Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Yonina R. Murciano‐Goroff(Memorial Sloan Kettering Cancer Center), Joshua K. Sabari(NYU Langone Health), Ji‐Youn Han(National Cancer Centre Japan), Philippe A. Cassier(Centre Léon Bérard), Rasha Cosman(UNSW Sydney), Takafumi Koyama(Tokyo National Hospital), Timothy F. Burns(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Alexander I. Spira(Virginia Cancer Specialists), Toshio Shimizu(Wakayama Medical University), Dustin A. Deming(University of Wisconsin–Madison), Sophie Callies, Sae‐Won Han(Seoul National University Hospital), Justin Call, Yasutoshi Kuboki(National Cancer Center Hospital East), Misako Nagasaka(University of California, Irvine), Rebecca S. Heist(Massachusetts General Hospital), Amita Patnaik(South Texas Accelerated Research Therapeutics), Arjun Vasant Balar(NYU Langone Health), Quincy Siu-chung Chu(Alberta Health Services), Melinda D. Willard, Antoine Hollebecque(Institut Gustave Roussy), Shiyao Liu(Southern Medical University), Natraj Reddy Ammakkanavar(Community Health Network), Gregory A. Durm(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Wade T. Iams(Vanderbilt University Medical Center)
Cited by 37
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k